Dr. An H. Pham, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Hahnemann University College of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,185
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Hahnemann University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
PA license MD042011E -
Critical Care Medicine (Internal Medicine) Physician
PA license MD042011E
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Lehigh Valley Hospital Allentown, PA
- Paoli Hospital Paoli, PA
- Reading Hospital West Reading, PA
- Phoenixville Hospital Phoenixville, PA
- Pottstown Hospital Pottstown, PA
Medical groups
- Pottstown Medical Specialists Inc (40 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,185
- Services billed
- 80,399
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, mepolizumab, 1 mg | 18,434 | 24 |
| Injection, omalizumab, 5 mg | 10,944 | 11 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,671 | 786 |
| Injection, benralizumab, 1 mg | 1,292 | 11 |
| Injection of drug or substance under skin or into muscle | 1,071 | 184 |
| Test to measure expiratory airflow and volume | 835 | 533 |
| Established patient office or other outpatient visit, 30-39 minutes | 530 | 292 |
| Test to determine lung volumes using gas dilution or washout | 480 | 423 |
| Test to examine how well the lungs exchange gases | 472 | 418 |
| Injection, methylprednisolone acetate, 80 mg | 280 | 153 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Pottstown, PA | 856 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Pottstown, PA | 443 |
| Montelukast Sodium Other prescribers in Pottstown, PA | 369 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Pottstown, PA | 323 |
| Prednisone Other prescribers in Pottstown, PA | 214 |
| Zolpidem Tartrate Other prescribers in Pottstown, PA | 160 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Pottstown, PA | 150 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Pottstown, PA | 142 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Pottstown, PA | 138 |
| Theophylline Er (theophylline anhydrous) Other prescribers in Pottstown, PA | 115 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 297 payments worth $6,587 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $1,322 |
|---|---|
| Verona Pharma, Inc. | $720 |
| Genzyme Corporation | $710 |
| GlaxoSmithKline, LLC. | $396 |
| Harmony Biosciences LLC | $334 |
| Mallinckrodt Hospital Products Inc. | $308 |
| Insmed, Inc. | $299 |
| Actelion Pharmaceuticals US, Inc. | $295 |
| Food and Beverage | $6,137 |
|---|---|
| Consulting Fee | $350 |
| Education | $99.95 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Adempas · Cardio-pulmonary | $200 |
| Avadel Cns Pharmaceuticals, LLC Jan 17, 2025 | Consulting Fee LUMRYZ · CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | $150 |
| Sanofi-aventis U.S. LLC Jul 15, 2025 | Education DUPIXENT · Immunology · in-kind | $99.95 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $125,663 in research payments for these studies, mostly to the institutions running them.
- A twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults w…
AstraZeneca Pharmaceuticals LP - Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Sanofi US Services Inc. · Completed · NCT06102005 - Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
AstraZeneca Pharmaceuticals LP - A randomized, double-blind, parallel group, multi-center study to eval
GlaxoSmithKline, LLC. - A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.